Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F C Nelson

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Expert Opinion on Investigational Drugs|July 5, 2005
The therapeutic potential of small molecule TACE inhibitorsF C Nelson, A Zask
Canadian Journal of Comparative Medicine : Revue Canadienne De Medecine Comparee|April 1, 1976
Bovine mastitis in Ontario due to Mycoplasma agalactiae subsp. bovisH L Ruhnke, D Thawley, F C Nelson
Bioorganic & Medicinal Chemistry Letters|February 18, 1999
Manipulation of the C(22)-C(27) region of rapamycin: stability issues and biological implicationsF C Nelson, S J Stachel, C P Eng, et al.
Annals of the New York Academy of Sciences|July 23, 1999
Design and synthetic considerations of matrix metalloproteinase inhibitorsJ S Skotnicki, A Zask, F C Nelson, et al.
The American Review of Respiratory Disease|December 1, 1989
Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivityP K Jeffery, A J Wardlaw, F C Nelson, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2002
Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' groupJ I Levin, J M Chen, M T Du, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinasesJ I Levin, Y Gu, F C Nelson, et al.
Bioorganic & Medicinal Chemistry Letters|August 22, 2001
The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groupsJ I Levin, J Chen, M Du, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2001
The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic aminesJ I Levin, J M Chen, M T Du, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Expert Opinion on Investigational Drugs|July 5, 2005
The therapeutic potential of small molecule TACE inhibitorsF C Nelson, A Zask
Canadian Journal of Comparative Medicine : Revue Canadienne De Medecine Comparee|April 1, 1976
Bovine mastitis in Ontario due to Mycoplasma agalactiae subsp. bovisH L Ruhnke, D Thawley, F C Nelson
Bioorganic & Medicinal Chemistry Letters|February 18, 1999
Manipulation of the C(22)-C(27) region of rapamycin: stability issues and biological implicationsF C Nelson, S J Stachel, C P Eng, et al.
Annals of the New York Academy of Sciences|July 23, 1999
Design and synthetic considerations of matrix metalloproteinase inhibitorsJ S Skotnicki, A Zask, F C Nelson, et al.
The American Review of Respiratory Disease|December 1, 1989
Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivityP K Jeffery, A J Wardlaw, F C Nelson, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2002
Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' groupJ I Levin, J M Chen, M T Du, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinasesJ I Levin, Y Gu, F C Nelson, et al.
Bioorganic & Medicinal Chemistry Letters|August 22, 2001
The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groupsJ I Levin, J Chen, M Du, et al.
Bioorganic & Medicinal Chemistry Letters|October 26, 2001
The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic aminesJ I Levin, J M Chen, M T Du, et al.
Pageof 1